This job is no longer available
The successful candidate will be examining the delivery of antisense oligonucleotides and siRNAs via a novel technology to cells that are naturally primed for gene silencing. Experiments will be carried out both in vitro, and in human tumor xenografts in immunocompromised mice. The major goal of the project is to improve delivery without increasing cost or toxicity, while minimizing oligo concentration.
Minimum Education and Skills Required for Consideration:
• Ph.D. in life sciences.
About City of Hope
City of Hope, an innovative biomedical research, treatment and educational institution with over 4000 employees, is dedicated to the prevention and cure of cancer and other life-threatening diseases and guided by a compassionate, patient-centered philosophy.
Founded in 1913 and headquartered in Duarte, California, City of Hope is a remarkable non-profit institution, where compassion and advanced care go hand-in-hand with excellence in clinical and scientific research. City of Hope is a National Cancer Institute designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network, an alliance of the nation’s 20 leading cancer centers that develops and institutes standards of care for cancer treatment.
City of Hope strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced. Equal Opportunity / Affirmative Action Employer.